Drugs / Allogeneic peripheral blood stem cell
last change Oct 2019 re-read 2 minutes ago

Allogeneic peripheral blood stem cell

Cell therapy

Developed for
chronic granulomatous disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

202020212022202320242025202620272028202920302031203220332034
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT03910452 Oct 2019 → Jun 2034 expected chronic granulomatous disease National Institute of Allergy and Infectious Diseases (NIAID) Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic peripheral blood stem cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT03910452
Modality Cell therapy “IV infused donor peripheral blood stem cell” NCT03910452
Route Intravenous “IV infused donor peripheral blood stem cell” NCT03910452